CLAIMS

1. Use of Compound I



I

or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a medicament for treating a myeloproliferative disorder, wherein Compound I is to be administered to a patient previously treated with ruxolitinib.

2. The use according to claim 1, wherein the myeloproliferative disorder is resistant or refractory to ruxolitinib.

3. The use according to claim 1 or claim 2, wherein the patient is intolerant to ruxolitinib.

4. The use according to claim 3, wherein the intolerance to ruxolitinib is evidenced by a hematological toxicity or a non-hematological toxicity.

5. The use according to claim 1 or claim 2, wherein the patient has relapsed.

6. The use according to claim 1 or claim 2, wherein the patient has exhibited or experienced one or more of the following during treatment with ruxolitinib: lack of response, disease progression, or loss of response.

7. The use according to claim 6, wherein disease progression is evidenced by an increase in spleen size.

8 Use of Compound I



I

or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a medicament for reducing spleen volume by at least 25% in a patient suffering from or diagnosed with a myeloproliferative disorder, wherein Compound I is to be administered to a patient previously treated with ruxolitinib.

9. The use according to claim 8, wherein the patient's spleen volume is reduced by at least 35%.

10. Use of Compound I



I

or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a medicament for improving overall survival in a patient suffering from or diagnosed with a myeloproliferative disorder, wherein Compound I is to be administered to a patient previously treated with ruxolitinib.

11. Use of Compound I



I

or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a medicament for improving symptom response rate in a patient suffering from or diagnosed with a

myeloproliferative disorder, wherein Compound I is to be administered to a patient previously treated with ruxolitinib.

12. The use according to claim 11, wherein symptom response rate is evidenced by at least 50% reduction in total symptom score (TSS).

13. Use of Compound I



I

or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a medicament for increasing the median survival in a patient population suffering from or diagnosed with a myeloproliferative disorder that has relapsed and/or is refractory to ruxolitinib, wherein Compound I is to be administered to a patient previously treated with ruxolitinib.

14. Use of Compound I



I

or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a medicament for decreasing allele burden in a patient having a somatic mutation or clonal marker associated with or indicative of a myeloproliferative disorder, wherein Compound I is to be administered to a patient previously treated with ruxolitinib.

15. The use according to claim 14, wherein the somatic mutation is selected from a JAK2 mutation, a CALR mutation or a MPL mutation.

16. The use according to claim 15, wherein the JAK2 mutation is V617F.

17. The use according to claim 15, wherein the CALR mutation is a mutation in exon 9.

18. The use according to claim 15, wherein the MPL mutation is selected from W515K and W515L.

19. The use according to any of claims 1-18, wherein the myeloproliferative disorder is selected from intermediate risk MPN-associated myelofibrosis and high risk MPN-associated myelofibrosis.

20. The use according to claim 19, wherein the intermediate risk MPN-associated myelofibrosis is selected from primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis.

21. The use according to claim 19, wherein the high risk MPN-associated myelofibrosis is selected from primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis.

22. The use according to any of claims 1-21, wherein Compound I is in the form of a dihydrochloride monohydrate.

23. The use according to any of claims 1-22, wherein the patient has been previously treated with ruxolitinib for at least 3 months.

24. The use according to any of claims 1-22, wherein the patient has been previously treated with ruxolitinib for at least 28 days complicated by

i. development of a red blood cell transfusion requirement; or

ii. Grade ≥ 3 adverse event(s) of thrombocytopenia, anemia, hematoma, and/or hemorrhage while on treatment with ruxolitinib.

25. The use according to any of claims 1-24, wherein the dose of Compound I, or a pharmaceutically acceptable salt thereof, is about 400 mg, based on the free base weight of Compound I.